MDGL insiders sold 153,648 shares via 10b5-1; proposed $46.4M sale disclosed
Rhea-AI Filing Summary
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 129,172 shares of Common stock to be effected through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $46,372,748. The shares were acquired by the filer through the exercise of stock options on 08/13/2025 and payment was in cash.
The filing also lists multiple recent Rule 10b5-1 sales by two insiders, Rebecca Taub and Paul A. Friedman, showing combined sales of 153,648 shares in the past three months that generated approximately $54,457,408 in gross proceeds. The form includes the standard representation that the seller does not possess undisclosed material adverse information.
Positive
- None.
Negative
- Planned sale of 129,172 shares acquired by option exercise with an aggregate market value of $46,372,748 to be sold via Morgan Stanley on NASDAQ.
- Multiple 10b5-1 insider sales totaling 153,648 shares in the past three months, generating approximately $54,457,408 in gross proceeds (Rebecca Taub and Paul A. Friedman combined).
Insights
TL;DR: Routine Form 144 for an insider sale by option exercise; multiple recent 10b5-1 sales generated sizable gross proceeds.
The filing documents a planned sale of 129,172 shares acquired by exercise of options on 08/13/2025, to be sold through Morgan Stanley on NASDAQ for an aggregate market value of $46,372,748. The record of recent 10b5-1 transactions shows combined insider sales of 153,648 shares producing roughly $54.46M in gross proceeds over the past three months. These are factual disclosures of executed and proposed sales under Rule 144 and 10b5-1; they reflect liquidity events by insiders rather than operating results.
TL;DR: Disclosure follows standard Rule 144 and 10b5-1 formats with the usual certification about non-public material information.
The Form 144 identifies the seller, broker (Morgan Stanley Smith Barney LLC Executive Financial Services), the class of security, and the acquisition method (exercise of stock options) with cash payment. The document also details multiple 10b5-1 sales by named insiders with itemized dates, amounts, and gross proceeds. The filing contains the typical representation that the filer does not possess material undisclosed information, consistent with regulatory requirements for these notices.